You are now leaving
www.aplenzin.com. This link will take you to a website to which our Privacy Policy does not apply.
You are solely responsible for your interactions with that website.
APLENZIN is the only bupropion hydrobromide approved for the treatment of major depressive disorder (MDD), and the prevention of seasonal affective disorder (SAD).1
About APLENZINMultiple clinical studies have shown APLENZIN to be effective in treating MDD and SAD.1,2
Multiple clinical studies have shown APLENZIN to be effective in treating MDD and SAD.1,2
Appropriate treatment choice across different patient scenarios.
With the Copay Savings Program, eligible* commercially insured patients may pay as little as $5 for a 30-day supply.
With the Copay Savings Program, eligible* commercially insured patients may pay as little as $5 for a 30-day supply.
Start your patients on APLENZIN in the office with free samples.
REFERENCES:
APLENZIN® (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder (MDD), and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
SUICIDALITY AND ANTIDEPRESSANT DRUGS:
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older.
In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.
Contraindications
APLENZIN is contraindicated in:
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Special Populations
To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Click here for full Prescribing Information including Boxed Warning regarding suicidal thoughts and behaviors.
APLENZIN® (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder (MDD), and for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient.
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
SUICIDALITY AND ANTIDEPRESSANT DRUGS:
Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term trials. These trials did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in subjects aged 65 and older.
In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber.